期刊
JOURNAL OF CARDIAC FAILURE
卷 14, 期 6, 页码 521-530出版社
CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
DOI: 10.1016/j.cardfail.2008.02.016
关键词
autoimmune; heart failure; immunoadsorption; intravenous immunoglobulin; inflammation
资金
- National Institutes of Health, National Center for Research Resources [CTSA 1UL1RR024989]
- Amgen Inc
- [Abbott Diagnostics, Inc]
Dilated cardiomyopathy is a devastating disease associated with poor outcomes. Although the etiology of remains largely unknown, so-called idiopathic dilated cardiomyopathy (iDCM) is associated with evidence of an autoimmune process that may be contributing to the pathophysiology of this disease. Indeed, iDCM shares many characteristics with other autoimmune diseases, including an association with systemic and organ-specific inflammation, an association with viral infections, a genetic predisposition, and a correlation with specific human leukocyte antigen subtypes. Additionally, numerous pathologic cardiac-specific autoantibodies have been associated with iDCM, including those against alpha-myosin, the beta(1)-adrenoceptor, and cardiac troponin 1. This review highlights the emerging evidence regarding autoimmune characteristics of iDCM, and summarizes the data of specific immunomodulatory therapies used to target autoimmune mechanisms in the treatment of patients with this devastating disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据